InsidersTradesSigma
Track the Vitae Pharmaceuticals, Inc share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 25 January 2016 (Levée d'options). Among the most active insiders: Gregg Richard. Every trade is openly available.
Analysts rate Vitae Pharmaceuticals, Inc Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Vitae Pharmaceuticals, Inc is a biopharmaceutical company focused on developing treatments for genetic diseases and metabolic disorders. It is listed on NASDAQ under the ticker symbol VTAE.